BNC 210

Drug Profile

BNC 210

Alternative Names: BNC210; IW 2143

Latest Information Update: 06 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bionomics
  • Class Antidepressants; Anxiolytics; Small molecules
  • Mechanism of Action Adenosine A3 receptor modulators; Alpha7 nicotinic acetylcholine receptor antagonists; Neurokinin 2 receptor modulators; Phospholipase C modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Agitation; Anxiety disorders; Post-traumatic stress disorders
  • No development reported Depressive disorders

Most Recent Events

  • 24 May 2018 Phase-II clinical trials in Agitation (In the elderly) in Australia (PO)
  • 24 May 2018 Bionomics completes enrolment in the phase II (RESTORE) trial for Post-traumatic stress disorder (PTSD) in Australia (NCT02933606)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Anxiety-disorders(In volunteers) in France (PO, Suspension)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top